TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome.

Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Print ISSN: 0021-9738 (Print) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE

Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation
Original Publication: New Haven [etc.] American Society for Clinical Investigation.

Marfan Syndrome/*pathology ; Microfilament Proteins/*metabolism ; Mitral Valve Prolapse/*metabolism ; Mitral Valve Prolapse/*pathology ; Transforming Growth Factor beta/*metabolism; Animals ; Bone Morphogenetic Proteins/genetics ; Bone Morphogenetic Proteins/metabolism ; Disease Models, Animal ; Female ; Fibrillin-1 ; Fibrillins ; Humans ; Male ; Marfan Syndrome/genetics ; Marfan Syndrome/metabolism ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Microfilament Proteins/genetics ; Mitral Valve/anatomy & histology ; Mitral Valve/metabolism ; Mitral Valve/pathology ; Mitral Valve Prolapse/genetics ; Phenotype ; Pregnancy

Mitral valve prolapse (MVP) is a common human phenotype, yet little is known about the pathogenesis of this condition. MVP can occur in the context of genetic syndromes, including Marfan syndrome (MFS), an autosomal-dominant connective tissue disorder caused by mutations in fibrillin-1. Fibrillin-1 contributes to the regulated activation of the cytokine TGF-beta, and enhanced signaling is a consequence of fibrillin-1 deficiency. We thus hypothesized that increased TGF-beta signaling may contribute to the multisystem pathogenesis of MFS, including the development of myxomatous changes of the atrioventricular valves. Mitral valves from fibrillin-1-deficient mice exhibited postnatally acquired alterations in architecture that correlated both temporally and spatially with increased cell proliferation, decreased apoptosis, and excess TGF-beta activation and signaling. In addition, TGF-beta antagonism in vivo rescued the valve phenotype, suggesting a cause and effect relationship. Expression analyses identified increased expression of numerous TGF-beta-related genes that regulate cell proliferation and survival and plausibly contribute to myxomatous valve disease. These studies validate a novel, genetically engineered murine model of myxomatous changes of the mitral valve and provide critical insight into the pathogenetic mechanism of such changes in MFS and perhaps more common nonsyndromic variants of mitral valve disease.

Comment in: J Clin Invest. 2004 Dec;114(11):1543-6. (PMID: 15578086)

J Clin Invest. 1990 Feb;85(2):587-90. (PMID: 2153712)
Am J Pathol. 1989 Dec;135(6):1073-88. (PMID: 2596571)
Mol Endocrinol. 1994 Feb;8(2):148-58. (PMID: 8170471)
DNA Cell Biol. 1994 Jun;13(6):571-84. (PMID: 8024701)
Am Heart J. 1995 Jun;129(6):1149-58. (PMID: 7754947)
J Cell Biol. 1995 Oct;131(2):539-49. (PMID: 7593177)
J Mol Cell Cardiol. 1996 Feb;28(2):243-52. (PMID: 8729057)
Nat Genet. 1997 Mar;15(3):247-51. (PMID: 9054935)
Hypertension. 1998 Aug;32(2):273-9. (PMID: 9719054)
Clin Immunol. 1999 Jul;92(1):6-13. (PMID: 10413648)
J Cardiovasc Pharmacol. 1999 Aug;34(2):254-60. (PMID: 10445677)
Nature. 1991 Jul 25;352(6333):337-9. (PMID: 1852208)
Anat Rec. 2000 Feb 1;258(2):119-27. (PMID: 10645959)
Nat Genet. 2000 Feb;24(2):171-4. (PMID: 10655064)
Annu Rev Med. 2000;51:481-510. (PMID: 10774478)
Biochem Biophys Res Commun. 2000 Aug 2;274(2):267-74. (PMID: 10913330)
J Am Coll Cardiol. 2000 Oct;36(4):1411-8. (PMID: 11028503)
Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6. (PMID: 11134512)
J Cardiovasc Pharmacol. 2001 Feb;37(2):219-26. (PMID: 11210004)
J Biol Chem. 2001 May 25;276(21):17871-7. (PMID: 11278410)
Dev Biol. 2001 Jul 15;235(2):449-66. (PMID: 11437450)
J Cell Biol. 2001 Jul 23;154(2):275-81. (PMID: 11470817)
Genome Biol. 2001;2(8):RESEARCH0032. (PMID: 11532216)
Cardiovasc Pathol. 2002 Mar-Apr;11(2):69-77. (PMID: 11934597)
Biochem Biophys Res Commun. 2002 Jun 28;294(5):940-8. (PMID: 12074567)
Dev Biol. 2002 Aug 1;248(1):170-81. (PMID: 12142029)
J Endod. 2002 Dec;28(12):803-5. (PMID: 12489647)
J Biol Chem. 2003 Jan 24;278(4):2750-7. (PMID: 12429738)
Nat Genet. 2003 Mar;33(3):407-11. (PMID: 12598898)
Nat Genet. 2003 Apr;33(4):487-91. (PMID: 12612583)
EMBO J. 2003 Jun 2;22(11):2704-16. (PMID: 12773386)
J Comp Pathol. 2003 Aug-Oct;129(2-3):120-30. (PMID: 12921717)
Genes Dev. 2003 Oct 1;17(19):2362-7. (PMID: 12975322)
Mol Genet Metab. 2003 Sep-Oct;80(1-2):27-35. (PMID: 14567955)
Birth Defects Res C Embryo Today. 2004 Mar;72(1):37-50. (PMID: 15054903)
Dev Biol. 2004 May 15;269(2):505-18. (PMID: 15110716)
J Clin Invest. 2004 Jul;114(2):172-81. (PMID: 15254584)
J Cell Biol. 1989 Feb;108(2):653-60. (PMID: 2465297)
Mol Cell Biol. 1989 Dec;9(12):5508-15. (PMID: 2586525)

HL067056 United States HL NHLBI NIH HHS; HL53325 United States HL NHLBI NIH HHS; R01 AR041135 United States AR NIAMS NIH HHS; P01 AR049698 United States AR NIAMS NIH HHS; AR41135 United States AR NIAMS NIH HHS; K08 HL067056 United States HL NHLBI NIH HHS; R37 HL053325 United States HL NHLBI NIH HHS; R01 HL053325 United States HL NHLBI NIH HHS; AR049698 United States AR NIAMS NIH HHS

0 (Bone Morphogenetic Proteins)
0 (FBN1 protein, human)
0 (Fbn1 protein, mouse)
0 (Fibrillin-1)
0 (Fibrillins)
0 (Microfilament Proteins)
0 (Transforming Growth Factor beta)

Date Created: 20041117 Date Completed: 20050208 Latest Revision: 20181113

20231215

PMC529498

10.1172/JCI22715

15546004